Investors Alert: Deadline Approaches for Pacira BioSciences Class Action Lawsuit

Investor Alert: Class Action Lawsuit Against Pacira BioSciences

Former Louisiana Attorney General Charles C. Foti, Jr., along with Kahn Swick & Foti, LLC (KSF), has put out an important reminder for investors regarding a class action lawsuit against Pacira BioSciences, Inc. If you have incurred losses exceeding $100,000 and purchased securities of Pacira between August 2, 2023, and August 8, 2024, you may be eligible to take legal action.

Important Details

Investors must file lead plaintiff applications before March 14, 2025. The class action is rooted in allegations that Pacira and certain executives failed to disclose crucial information during the specified time frame, potentially resulting in significant financial losses for shareholders. This legal action is currently unfolding at the United States District Court for the District of New Jersey.

The Allegations

The lawsuit stems from a significant disclosure made by Pacira regarding its Exparel product, which constitutes roughly 80% of the company's revenue. On August 9, 2024, Pacira reported the outcome of litigation against eVenus, which centered on patent infringement claims pertaining to Exparel. The United States District Court ruled that Pacira's U.S. Patent No. 11,033,495 was invalid, implying that eVenus had not infringed on any of Pacira's intellectual property.

Following this announcement, Pacira's stock price plummeted over 47%, with shares dropping from a closing price of $22.36 on August 8 to a low of $11.70 on August 9. This dramatic fall illustrates the severe impact that these disclosures had on investor confidence and market valuation.

What Affected Investors Can Do

Affected individuals should reach out to KSF Managing Partner Lewis Kahn. He is available for consultations without any obligation or cost. You can contact him toll-free at 1-877-515-1850 or via email at [email protected]. Additionally, further details about this case can be explored at KSF's official website.

If interested in becoming a lead plaintiff in this class action, it is vital to act quickly and submit a petition to the Court before the deadline.

About Kahn Swick & Foti, LLC

KSF is recognized as a leading boutique law firm specializing in securities litigation. Founded by attorneys dedicated to pursuing justice for investors, the firm operates across multiple states, including offices in New York, California, Louisiana, Delaware, Chicago, and New Jersey. KSF seeks to represent public institutional investors, hedge funds, and individual investors affected by corporate fraud or malfeasance.

For legal clarity and representation, it is essential for affected Pacira investors to engage promptly. Remember that the window for taking legal action is limited, and proactive steps must be taken to safeguard your rights and potential recoveries.